Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.59 USD

87.59
5,119,705

-1.18 (-1.33%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $87.59 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Products

Zacks News

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) second-quarter results benefit from domestic and international revenue growth and solid new customer additions.

NextGen Healthcare (NXGN) Q1 Earnings & Revenues Top Estimates

NextGen Healthcare's (NXGN) fiscal first-quarter earnings reflect strong segmental performance.

Cerner (CERN) Q2 Earnings and Revenues Surpass Estimates

Cerner's (CERN) second-quarter results benefit from gains across six of its business units.

Company News for Jul 28, 2021

Companies In The News Are: RGEN, SIRI, BSX, FISV.

Boston Scientific (BSX) Q2 Earnings Beat, 2021 Guidance Up

Organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in Q2.

Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of 8.11% and 4.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Boston Scientific (BSX) Ahead of Earnings?

Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Boston Scientific (BSX) Watchman FLX Sales to Aid Q2 Earnings

Strong procedure recovery and market share gains across many of the businesses and regions are expected to have boosted Boston Scientific's (BSX) Q2 sales.

Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Avanos (AVNS) Stock for Now

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Riya Anand headshot

3 Stocks in Focus on Evolving MedTech Trends Amid COVID-19

Stocks like Allscripts Healthcare Solutions (MDRX), National Vision Holdings (EYE) and Quest Diagnostics (DGX) are in focus on evolving MedTech trends.

The Zacks Analyst Blog Highlights: Oracle, Lockheed Martin, Boston Scientific, Regeneron Pharmaceuticals and Eni

The Zacks Analyst Blog Highlights: Oracle, Lockheed Martin, Boston Scientific, Regeneron Pharmaceuticals and Eni

Mark Vickery headshot

Top Analyst Reports for Oracle, Lockheed Martin & Boston Scientific

Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Lockheed Martin (LMT), and Boston Scientific (BSX).

NVST vs. BSX: Which Stock Should Value Investors Buy Now?

NVST vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) Eyeing Remaining 73% Farapulse Stake

Boston Scientific (BSX) currently holds an equity stake of roughly 27%.

AngioDynamics (ANGO) Hits New 52-Week High: What's Driving It?

AngioDynamics (ANGO) is optimistic about maintaining its robust product portfolio.

Debanjana Dey headshot

Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on

These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.

NVST vs. BSX: Which Stock Should Value Investors Buy Now?

NVST vs. BSX: Which Stock Is the Better Value Option?

Boston Scientific (BSX) EXALT Gets CE Nod, Endoscopy Arm Grows

The European market release of Boston Scientific's (BSX) EXALT Model B Single-Use Bronchoscope will mitigate infection risks associated with reusable imaging scopes.

Quest Diagnostics (DGX) Base Business Rebounds Amid Price Woe

Contributions from acquisitions and Professional Lab Services relationships accelerate base business growth for Quest Diagnostics (DGX).

CVS Health (CVS) Gains From Digitalization, Hurt by Seasonality

CVS Health's (CVS) consumer-centric digital strategy is now more relevant in the current environment as people are using technology while staying indoors.

Here's Why You Should Add Phibro (PAHC) to Your Portfolio

Investors are optimistic about Phibro (PAHC) on solid third-quarter performance and potential in emerging markets.

Bruker's (BRKR) Research Tools Enable New insight on PACS

Bruker's (BRKR) quantitative NMR and MS assay platform together with Australian National Phenome Centre evaluate risk and longitudinal monitoring of post-acute COVID-19 syndrome.

Cardiovascular Systems (CSII) Coronary Arm Grows, Margin Dips

Cardiovascular Systems (CSII) is progressing well with its objective to introduce OAS globally.

Cardiovascular Systems (CSII) Coronary OAS Study Data Favorable

Cardiovascular Systems' (CSII) Diamondback 360 Coronary OAS helps in restoring native vessel compliance, simplify procedural workflow and enhance percutaneous coronary intervention outcomes.